Advanced Filters
noise

acute-myeloid-leukemia Clinical Trials

A listing of acute-myeloid-leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 566 clinical trials
G Gina Bellenger

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will …

18 years of age All Phase 2
M Maro Ohanian, DO

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

The goal of this clinical research study is to learn if metal detoxification (with calcium disodium edetate [Ca-EDTA] and dimercaptosuccinic acid [DMSA]) during standard therapy can help improve outcomes in patients with intermediate-risk, high-risk, or secondary AML compared to standard therapy alone. Researchers think lowering the level of metals found …

18 years of age All Phase 2
R Richard Lin, MD, PhD

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).

65 years of age All Phase 2
D Dominique GENRE, MD

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

The goal of this clinical trial is to test efficacy and safety of a VENETOCLAX-AZACITIDINE (VEN-AZA) de-escalation strategy in Acute Myeloid Leukemia responding patients. The main objectives of the study are: Evaluation of the efficacy of VEN-AZA de-escalation strategy by measuring the effect of VEN-AZA discontinuation in term of Disease-Free …

18 years of age All Phase 2

Clinical Study of U32 in Patients With Acute Myeloid Leukemia

This is a single-arm, open-label clinical study to evaluate the safety, tolerability, and efficacy of U32 injection in patients with acute myeloid leukemia.

2 - 65 years of age All Phase 1/2
C Curtis A. Lachowiez

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell growth in LSD1-overexpressing cancer cells. Chemotherapy drugs, …

18 years of age All Phase 1
C Clinical Research Group

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation …

18 years of age All Phase 2
A Amandeep Salhotra

Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant

This phase I trial studies the side effects of using enasidenib as maintenance therapy in treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

18 years of age All Phase 1
C Courtney Schepel

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

The purpose of this research is to see how personal financial burden (financial toxicity) related to cancer affects the overall health and quality of life by evaluating the impact of systematic financial navigation in addition to standard financial distress interventions during cancer treatment.

18 - 64 years of age All Phase N/A
I Iben H Nielsen, Clinical Nurse Specialist, PhD

Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia

The aim is to investigate the feasibility, safety, and complication rates of patient's self-measurement of CBC and self-administration of blood and platelet transfusions at home and examine the performance of patients conducting at-home monitoring of their blood pressure, pulse rate, saturation, and temperature before and after transfusion. Furthermore, to evaluate …

18 years of age All Phase N/A

Simplify language using AI